相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Targeting immune checkpoints in non small cell lung cancer
Andrea Bianco et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)
R. Ferrara et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
M. Reck et al.
ANNALS OF ONCOLOGY (2017)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
S. Burdett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
